AR035723A1 - Compuesto derivado de 1,5 benzotiazepina, procedimiento para su preparacion, composicion farmaceutica, y,combinacion que lo comprenden y su uso en la fabricacion de un medicamento - Google Patents

Compuesto derivado de 1,5 benzotiazepina, procedimiento para su preparacion, composicion farmaceutica, y,combinacion que lo comprenden y su uso en la fabricacion de un medicamento

Info

Publication number
AR035723A1
AR035723A1 ARP010106011A ARP010106011A AR035723A1 AR 035723 A1 AR035723 A1 AR 035723A1 AR P010106011 A ARP010106011 A AR P010106011A AR P010106011 A ARP010106011 A AR P010106011A AR 035723 A1 AR035723 A1 AR 035723A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
independently selected
carbamoyl
sulfamoyl
Prior art date
Application number
ARP010106011A
Other languages
English (en)
Inventor
Ingemar Starke
Mikael Dahlstrom
David Blomberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0004811A external-priority patent/SE0004811D0/xx
Priority claimed from GB0112592A external-priority patent/GB0112592D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR035723A1 publication Critical patent/AR035723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto derivado de 1,5 benzotiazepina de fórmula (1): donde: Rv y Rw se seleccionan independientemente entre hidrógeno o alquilo C1-6; R1 y R2 se seleccionan independientemente entre hidrógeno y alquilo C1-6; Rx y Ry se seleccionan independientemente entre hidrógeno o alquilo C1-6, o uno de Rx y Ry es hidrógeno o alquilo C1-6 y el otro es hidroxi o alcoxi C1-6; Rz se selecciona entre halo, nitro, ciano, hidroxilo, amino, carboxi, carbamoílo, mercapto, sulfamoílo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoílo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoílo, alquil C1-6S(O)a donde a es 0 a 2; alcoxicarbonilo C1-6, alcoxicarbonilamino C1-6, ureido, N'-(alquil C1-6)ureido, N-(alquil C1-6)ureido, N',N'-(alquil C1-6)2ureido, N'-(alquil C1-6)-N-(alquil C1-6)ureido, N',N'-(alquil C1-6)2-N-(alquil C1-6)ureido, N-(alquil C1-6)sulfamoílo y N,N-(alquil C1-6)2sulfamoílo; v es 0-5; uno de R4 y R5 es un grupo de fórmula (2): donde R3 y R6 y el otro de R4 y R5 se seleccionan independientemente entre hidrógeno, halo, nitro, ciano, hidroxilo, amino, carboxi, carbamoílo, mercapto, sulfamoílo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcanoílo C1-4, alcanoiloxi C1-4, N-(alquil C1-4)amino, N,N-(alquil C1-4)2amino, alcanoilamino C1-4, N-(alquil C1-4)carbamoílo, N,N-alquil C1-4)2carbamoílo, alquil C1-4S(O)a donde a es entre 0 y 2, alcoxicarbonilo C1-4, N-(alquil C1-4)sulfamoílo y N,N-(alquil C1-4)2sulfamoílo; donde R3 y R6 y el otro de R4 y R5 puede ser opcionalmente sustituido en un carbono por uno o más R16; D es -O-; -N(Ra)-, -S(O)b- o -CH(Ra)-; donde Ra es hidrógeno o alquilo C1-6 y b es 0-2; el anillo A es arilo o heteroarilo; donde el anillo A es opcionalmente sustituido por uno o más sustituyentes seleccionados de R17; R7 es hidrógeno, alquilo C1-4, carbociclilo o heterociclilo; donde R7 es optativamente sustituido por uno o más sustituyentes seleccionados entre R18; R8 es hidrógeno o alquilo C1-4; R9 es hidrógeno o alquilo C1-4; R10 es hidrógeno, alquilo C1-4, carbociclilo o heterociclilo; donde R10 es optativamente sustituido por uno o más sustituyentes seleccionados entre R19; R11 es carboxi, sulfo, sulfino, fosfono, tetrazolilo, -P(O)(ORc)(ORd), -P(O)(OH)(ORc), -P(O)(OH)(Rd) o -P(O)(ORc)(Rd) donde Rc y Rd se seleccionan independientemente entre alquilo C1-6; o R11 es un grupo de fórmula (3) donde: X es -N(Rq)-, -N(Rq)C(O)-, -O-, y -S(O)a-; donde a es 0-2 y Rq es hidrógeno o alquilo C1-4; R12 es hidrógeno o alquilo C1-4; R13 y R14 se seleccionan independientemente entre hidrógeno, alquilo C1-4, carbociclilo, heterociclilo o R23; donde dicho alquilo C1-4, carbociclilo o heterociclilo pueden ser independientemente y optativamente sustituidos por uno o más sustituyentes seleccionados entre R20; R15 es carboxi, sulfo, sulfino, fosfono, tetrazolilo, -P(O)(ORe)(ORf), -P(O)(OH)(ORe), -P(O)(OH)(Re) o -P(O)(ORe)(Rf) donde Re y Rf se seleccionan independientemente entre alquilo C1-6; o R15 es un grupo de fórmula (4): donde: R24 se selecciona entre hidrógeno o alquilo C1-4; R25 se seleccionan entre hidrógeno, alquilo C1-4, carbociclilo, heterociclilo o R27; donde dicho alquilo C1-4, carbociclilo o heterociclilo puede ser opcionalmente sustituido en forma independiente por uno o mas sustituyentes seleccionados entre R28; R26 se selecciona entre carboxi, sulfo, sulfino, fosfono, tetrazolilo, -P(O)(ORg)(ORh ), P(O)(OH)(ORg), -P(O)(OH)(Rg) o -P(O)(ORg)(Rh) donde Rg y Rh se seleccionan independientemente entre alquilo C1-6; p es 1-3; donde los valores de R13 pueden ser iguales o diferente; q es 0-1; r es 0-3; donde los valores de R14 pueden ser iguales o diferentes; m es 0-2; donde los valores de R10 pueden ser iguales o diferentes; n es 1-3; donde los valores de R7 pueden ser iguales o diferentes; z es 0-3; donde los valores de R25 pueden ser iguales o diferentes; R16, R17 y R18 se seleccionan independientemente entre halo, nitro, ciano, hidroxilo, amino, carboxi, carbamoílo, mercapto, sulfamoílo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcanoílo C1-4, alcanoiloxi C1-4; N-(alquil C1-4)amino, N,N-(alquil C1-4)2amino, alcanoilamino C1-4, N-(alquil C1-4)carbamoílo, NN-(alquil C1-4)2carbamoílo, alquil C1-4S(O)a donde a es entre 0 y 2; alcoxicarbonilo C1-4, N-(alquil C1-4)sulfamoílo y N,N-(alquil C1-4)2sulfamoílo; donde R16, R17 y R18 pueden ser independientemente y optativamente sustituidos en un carbono por uno o más R21; R19, R20, R23, R27 y R28 se seleccionan independientemente entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoílo, mercapto, sulfamoílo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcanoílo C1-4, alcanoiloxi C1-4, N-(alquil C1-4)amino, N,N-(alquil C1-4)2amino, alcanoilamino C1-4, N-(alquil C1-4)carbamoílo, NN-(alquil C1-4)2carbamoílo, alquil C1-4S(O)a donde a es entre 0 y 2, alcoxicarbonilo C1-4, N-(alquil C1-4)sulfamoílo y N,N-(alquil C1-4)2sulfamoílo; carbociclilo, heterociclilo, sulfo, sulfino, amidino, fosfono, -P(O)(ORa)(ORb), -P(O)(OH)(ORa), -P(O)(OH)(Ra) o -P(O)(ORa)(Rb), donde Ra y Rb se seleccionan independientemente entre alquilo C1-6; donde R19, R20, R23, R27 y R28 pueden ser independientemente y optativamente sustituidos por uno o más R22; R21 y R22 se seleccionan independientemente entre halo, hidroxilo, ciano, carbamoílo, ureido, amino, nitro, carboxi, carbamoílo, mercapto, sulfamoílo, trifluorometilo, trifluorometoxi, metilo, etilo, metoxi, etoxi, vinilo, alilo, etinilo, metoxicarbonilo, formilo, acetilo, formamido, acetilamino, acetoxi, metilamino, dimetilamino, N-metilcarbamoilo, N,N-dimetilcarbamoílo, metiltio, metilsulfinilo, mesilo, N-metilsulfamoílo y N,N-dimetilsulfamoílo; o una sal, solvato, solvato de dicha sal o profármaco aceptable para uso farmacéutico del mismo. Estos compuestos se usan como inhibidores del transporte ileal de ácidos biliares (IBAT) para el tratamiento de la hiperlipidemia. Asimismo se describen los procesos para su fabricación y las composiciones farmacéuticas y combinaciones que los contienen.
ARP010106011A 2000-12-21 2001-12-21 Compuesto derivado de 1,5 benzotiazepina, procedimiento para su preparacion, composicion farmaceutica, y,combinacion que lo comprenden y su uso en la fabricacion de un medicamento AR035723A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0004811A SE0004811D0 (sv) 2000-12-21 2000-12-21 Chemical compounds
GB0112592A GB0112592D0 (en) 2001-05-24 2001-05-24 Chemical compounds

Publications (1)

Publication Number Publication Date
AR035723A1 true AR035723A1 (es) 2004-07-07

Family

ID=26246111

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106011A AR035723A1 (es) 2000-12-21 2001-12-21 Compuesto derivado de 1,5 benzotiazepina, procedimiento para su preparacion, composicion farmaceutica, y,combinacion que lo comprenden y su uso en la fabricacion de un medicamento

Country Status (33)

Country Link
US (1) US7192945B2 (es)
EP (1) EP1345918B1 (es)
JP (2) JP3665055B2 (es)
KR (1) KR100882342B1 (es)
CN (1) CN1268618C (es)
AR (1) AR035723A1 (es)
AT (1) ATE360008T1 (es)
AU (2) AU2222802A (es)
BG (1) BG66342B1 (es)
BR (1) BRPI0116397B8 (es)
CA (1) CA2431461C (es)
CY (1) CY1106664T1 (es)
CZ (1) CZ305032B6 (es)
DE (1) DE60127997T2 (es)
DK (1) DK1345918T3 (es)
EE (1) EE05158B1 (es)
EG (1) EG26979A (es)
ES (1) ES2284587T3 (es)
HK (1) HK1056732A1 (es)
HU (1) HU229050B1 (es)
IL (2) IL156341A0 (es)
IS (1) IS2833B (es)
MX (1) MXPA03005637A (es)
MY (1) MY137508A (es)
NO (1) NO326620B1 (es)
NZ (1) NZ526562A (es)
PL (1) PL219847B1 (es)
PT (1) PT1345918E (es)
RU (1) RU2302414C2 (es)
SA (1) SA02220610B1 (es)
SI (1) SI1345918T1 (es)
SK (1) SK287059B6 (es)
WO (1) WO2002050051A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP3616635B2 (ja) 2001-09-08 2005-02-02 アストラゼネカ アクチボラグ 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) * 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
WO2004000790A1 (en) 2002-06-20 2003-12-31 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EA013590B1 (ru) 2003-12-02 2010-06-30 Шварц Фарма Аг Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
CN102293773A (zh) * 2004-02-27 2011-12-28 旭化成制药株式会社 含有苯并硫氮杂卓和苯并虑平化合物的药物
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
ES2645529T3 (es) 2006-06-15 2017-12-05 Ucb Pharma Gmbh Composición farmacéutica con efecto sinérgico anticonvulsionante
KR101558005B1 (ko) * 2007-03-08 2015-10-06 알비레오 에이비 2-치환-3-페닐프로피온산 유도체 및 염증성 장 질환 치료에서의 그의 용도
JP2012509891A (ja) * 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
KR20130132846A (ko) * 2010-11-08 2013-12-05 알비레오 에이비 대사 장애들 및 관련 질환들의 치료용 ⅰｂａｔ 억제제들
EP2637668B1 (en) * 2010-11-08 2016-05-11 Albireo AB Ibat inhibitors for the treatment of liver diseases
SG190433A1 (en) 2010-11-08 2013-06-28 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
US20120114588A1 (en) * 2010-11-08 2012-05-10 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) * 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
KR102296314B1 (ko) 2014-06-25 2021-09-01 이에이 파마 가부시키가이샤 고형 제제 및 그의 안정화 방법
KR101674806B1 (ko) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) * 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
AU2019232477A1 (en) * 2018-03-09 2020-09-10 Elobix Ab Process for the preparation of elobixibat
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
LT3921028T (lt) 2019-02-06 2023-02-10 Albireo Ab Benzotiadiazepino junginiai ir jų naudojimas kaip tulžies rūgšties moduliatorių
BR112021015815A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para tratar colestase
JP7256540B2 (ja) * 2019-03-26 2023-04-12 国立大学法人東北大学 血中尿毒症物質の低減剤
CN115175918A (zh) * 2019-09-09 2022-10-11 埃洛比克斯股份公司 用于制造1,5-苯并硫氮杂䓬化合物的方法
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TW202134223A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
CA3158175A1 (en) * 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothiazepine compounds and their use as bile acid modulators
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
WO2023164179A1 (en) * 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN117980295A (zh) * 2022-08-02 2024-05-03 上海皓元医药股份有限公司 一种依洛西巴特晶型ii及其制备方法
WO2024094841A1 (en) 2022-11-03 2024-05-10 Albireo Ab Treating alagille syndrome (algs)
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
JPH05186357A (ja) 1991-12-31 1993-07-27 Shigeo Ochi 飲食物消化分解産物吸収抑制手段
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0781278T3 (da) 1994-09-13 2001-04-17 Monsanto Co Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
WO1997033882A1 (en) 1996-03-11 1997-09-18 G.D. Searle And Co. Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
EP0971744A2 (en) 1997-03-11 2000-01-19 G.D. SEARLE & CO. COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
ES2198613T3 (es) 1997-03-14 2004-02-01 Aventis Pharma Deutschland Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos.
AUPO763197A0 (en) 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
WO1999032478A1 (en) 1997-12-19 1999-07-01 G.D. Searle & Co. Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
MXPA01006470A (es) 1998-12-23 2003-06-06 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y agentes de secuentro de acido biliar para indicaciones cardiovasculares.
HUP0104793A2 (en) 1998-12-23 2002-06-29 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
IL143944A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations for cardiovascular indications
IL143938A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
JP2002536440A (ja) 1999-02-12 2002-10-29 ジー．ディー．サール エルエルシー 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規１，２−ベンゾチアゼピン
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP3616635B2 (ja) 2001-09-08 2005-02-02 アストラゼネカ アクチボラグ 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
SK7762003A3 (en) 2004-01-08
IS2833B (is) 2013-05-15
CA2431461C (en) 2011-02-08
JP3665055B2 (ja) 2005-06-29
SK287059B6 (sk) 2009-10-07
HU229050B1 (en) 2013-07-29
BG107928A (bg) 2004-08-31
CN1481373A (zh) 2004-03-10
PT1345918E (pt) 2007-06-27
DE60127997T2 (de) 2008-01-17
BRPI0116397B1 (pt) 2015-07-21
EE05158B1 (et) 2009-04-15
AU2222802A (en) 2002-07-01
RU2302414C2 (ru) 2007-07-10
CZ20031717A3 (cs) 2003-09-17
WO2002050051A1 (en) 2002-06-27
KR100882342B1 (ko) 2009-02-12
EP1345918A1 (en) 2003-09-24
IL156341A0 (en) 2004-01-04
HUP0301953A2 (hu) 2003-10-28
EG26979A (en) 2015-03-01
BR0116397A (pt) 2003-11-11
EE200300307A (et) 2003-10-15
HK1056732A1 (en) 2004-02-27
DE60127997D1 (de) 2007-05-31
CZ305032B6 (cs) 2015-04-08
PL363380A1 (en) 2004-11-15
IS6852A (is) 2003-06-18
BG66342B1 (bg) 2013-07-31
PL219847B1 (pl) 2015-07-31
EP1345918B1 (en) 2007-04-18
DK1345918T3 (da) 2007-07-16
NZ526562A (en) 2005-01-28
US7192945B2 (en) 2007-03-20
BRPI0116397B8 (pt) 2021-05-25
SA02220610B1 (ar) 2008-03-08
AU2002222228B2 (en) 2007-06-07
JP2004516285A (ja) 2004-06-03
ATE360008T1 (de) 2007-05-15
JP2004196815A (ja) 2004-07-15
NO326620B1 (no) 2009-01-19
MY137508A (en) 2009-02-27
CY1106664T1 (el) 2012-05-23
IL156341A (en) 2009-09-22
SI1345918T1 (sl) 2007-10-31
ES2284587T3 (es) 2007-11-16
MXPA03005637A (es) 2003-10-06
US20040067933A1 (en) 2004-04-08
NO20032829L (no) 2003-08-15
KR20030072572A (ko) 2003-09-15
CN1268618C (zh) 2006-08-09
CA2431461A1 (en) 2002-06-27
NO20032829D0 (no) 2003-06-20

Similar Documents

Publication Publication Date Title
AR035723A1 (es) Compuesto derivado de 1,5 benzotiazepina, procedimiento para su preparacion, composicion farmaceutica, y,combinacion que lo comprenden y su uso en la fabricacion de un medicamento
AR037089A1 (es) Derivado de 1,2 benzotiazepina o 1,2,5-benzotiadiazepina,proceso para su preparacion, composicion farmaceutica que lo comprende, y su uso en la fabricacion de un medicamento para la produccion de un efecto inhibidor de transporte ileal de acidos biliares
AR040408A1 (es) Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR041185A1 (es) Compuestos difenilazetidinona para tratar desordenes en el metabolismo de lipidos
AR049662A1 (es) Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer
AR053992A1 (es) Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR053683A1 (es) Derivados de piperidina con actividad antibacteriana
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
AR064130A1 (es) Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas.
HRP20100397T1 (hr) INHIBITORI 11-ß-HIDROKSISTEROID-DEHIDROGENAZE 1
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
AR041594A1 (es) Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1
AR047702A1 (es) Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular
AR055249A1 (es) Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas
AR054183A1 (es) Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
AR031251A1 (es) Derivado de pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento y proceso de preparacion
AR073760A1 (es) Derivados heterociclicos y metodos de uso de los mismos
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
CA2333322A1 (en) Nitric oxide synthase inhibitors
AR062406A1 (es) Derivados de quinazolina como inhibidores de b-raf

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee